ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
Treatments studied
Part of Cancer, Skin clinical trials.
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid tumor (not a blood cancer) with a confirmed EGFR or HER2 change—such as EGFR exon 20 insertion, atypical EGFR mutation (lung only), or HER2 exon 20 insertion, amplification, or overexpression.
- You have either had prior standard treatment and it stopped working/wasn’t tolerated, or you are in a cohort that allows treatment-naïve cases (depends on the exact subgroup).
- You can agree to a pretreatment biopsy (a tissue sample taken before starting the study medicine).
- Your cancer has measurable disease (can be tracked on scans) and your body is in good enough shape—ECOG performance status 0 or 1.
- Your brain/spinal involvement is acceptable: prior treated and controlled or, if untreated, you have no symptoms; you must not have leptomeningeal disease (unless specifically allowed by scan and no symptoms).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill (ORIC-114) combined with a targeted injection (amivantamab) for a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It aims to see if the combination shrinks tumors or delays growth.
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug called ORB-021 for people with advanced solid tumors that have come back or not responded to other treatments. The goal is to see if ORB-021 is safe and how it affects the body.
This study tests an experimental drug called IMC-R117C for people with certain advanced cancers. It aims to see if the drug can shrink tumors or slow cancer growth.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.